Infliximab in the treatment of plaque type psoriasis

Clinical, Cosmetic and Investigational Dermatology

Volumn 2, Issue , 2009, Pages 27-37

  Saraceno, Rosita ^a   Saggini, Andrea ^a   Pietroleonardo, Lucia ^a   Chimenti, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Infliximab; Long term treatment; Nail psoriasis; Psoriasis

Indexed keywords

ALEFACEPT; ANTIHISTAMINIC AGENT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 20; INTERLEUKIN 23; METHOTREXATE; PARACETAMOL; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ACTINOMYCOSIS; ADAPTIVE IMMUNITY; ADULT; ANKYLOSING SPONDYLITIS; BLOOD PRESSURE; CELL PROLIFERATION; CHEST TIGHTNESS; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CROSSOVER PROCEDURE; CRYPTOCOCCAL MENINGITIS; DESENSITIZATION; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ANAPHYLAXIS; DRUG BINDING; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPNEA; EARLY DIAGNOSIS; FLUSHING; HEART PALPITATION; HISTOPLASMOSIS; HUMAN; HYPERTENSION; HYPOTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE DEFICIENCY; INNATE IMMUNITY; KERATINOCYTE; LISTERIOSIS; LONG TERM CARE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAIL DISEASE; NAIL PSORIASIS; NAUSEA; PATHOGENESIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PITYRIASIS RUBRA PILARIS; PROVOCATION TEST; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUVA; PYODERMA GANGRENOSUM; PYREXIA IDIOPATHICA; QUALITY OF LIFE; RAISED TEMPERATURE; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; RIGOR; SEPSIS; SERUM SICKNESS; SIDE EFFECT; SKIN CANCER; SKIN INFLAMMATION; STRIDOR; SUPPURATIVE HIDRADENITIS; SWEATING; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS; URTICARIA; VISCERAL LEISHMANIASIS; WHEEZING;

EID: 77953422203     PISSN: None     EISSN: 11787015     Source Type: Journal    
DOI: 10.2147/ccid.s3413     Document Type: Review

References (81)

1. Griffths CEM, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263-271.
2. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-407.
3. Lebwohl M. Psoriasis. Lancet. 2003;361:1197-1204.
4. Green L, Meyers OL, Gordon W, Briggs B. Arthritis in psoriasis. Ann Rheum Dis. 1981;40(4):366-369.
5. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med. 1991;324:277-284.
6. Kuijpers AL, van de Kerkhof PC. Risk-benefi t assessment of methotrexate in the treatment of severe psoriasis. Am J Clin Dermatol. 2000;1(1):27-39.
7. Gasparro FP. The role of PUVA in the treatment of psoriasis. Photobiology issues related to skin cancer incidence. Am J Clin Dermatol. 2000;1(6):337-348.
8. Ghoreschi K, Weigert C, Röcken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol. 2007;25(6):574-580.
9. Santamaria Babi LF, Picker LJ, Perez Soler MT, et al. Circulating allergen-reactive T cells from patients with atopic dermatitis and allergic contact dermatitis express the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen. J Exp Med. 1995;181(5):1935-1940.
10. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128(5):1207-1211.
11. Nickoloff BJ, Xin H, Nestle FO, Qin JZ. The cytokine and chemokine network in psoriasis. Clin Dermatol. 2007;25(6):568-573.
12. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic infl ammatory disease. N Engl J Med. 1997;336:1066-1072.
13. Sumagin R, Sarelius IH. TNF-alpha activation of arterioles and venules alters distribution and levels of ICAM-1 and affects leukocyte-endothelial cell interactions. Am J Physiol Heart Circ Physiol. 2006;291(5):H2116-H2125.
14. Kimber I, Cumberbatch M, Dearman RJ, Bhushan M, Griffi ths CEM. Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization. Br J Dermatol. 2000;142:401-412.
15. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183-3194.
16. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-a monoclonal antibody cA2 binds recombinant transmembrane TNF-a and activates immune effector functions. Cytokine. 1995;7:251-259.
17. Kleyn CE, Griffi ths CE. Infliximab for the treatment of psoriasis. Expert Opin Biol Ther. 2006;6(8):797-805.
18. Di Sabatino A, Ciccocioppo R, Cinque B, et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut. 2004;53:70-77.
19. Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol. 2007;56:55-79.
20. Ruzzetti M, Saraceno R, Carboni I, Papoutsaki M, Chimenti S. Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximab. J Eur Acad Dermatol Venereol. 2008;22(1):117-118.
21. Mössner R, Schön MP, Reich K. Tumor necrosis factor antagonists in the therapy of psoriasis. Clin Dermatol. 2008;26(5):486-502.
22. Chaudhari U, Romano P, Mulcahy LD, et al. efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet. 2001;357:1842-1847.
23. Gottlieb AB, Chaudari U, Mulcahy LD, et al. Infliximab monotherapy provides rapid and substantial benefi t for plaque-type psoriasis. J Am Acad Dermatol. 2003;48:829-835.
24. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367-1374.
25. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol. 2005;153(3):486-497.
26. Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg. 2005;24(1):52-57.
27. Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159(2):274-285.
28. Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W. efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159(3):513-526.
29. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005;72:250-256.
30. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98(6):1315-1324.
31. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534-542.
32. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20(4):757-790.
33. Puchner TC, Kugathasan S, Kelly KJ, Binion DG. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Infl amm Bowel Dis. 2001;7(1):34-37.
34. Duburque C, Lelong J, Iacob R, et al. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Aliment Pharmacol Ther. 2006;24(5):851-858.
35. Lequerré T, Vittecoq O, Klemmer N, et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol. 2006;33(7):1307-1314.
36. Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cézard JP. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol. 2006;118(1):11-19.
37. Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA. Review and expert opinion on prevention and treatment of Infliximab-related infusion reactions. Br J Dermatol. 2008;159(3):527-536.
38. Baert F, Noman M, Vermeire S, et al. Infl uence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348(7):601-608.
39. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2(7): 542-553.
40. Kapetanovic MC, Larsson L, Truedsson L, Sturfelt G, Saxne T, Geborek P. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther. 2006;8(4):R131.
41. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56(9):1226-1231.
42. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther. 2003;17(1):75-84.
43. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003;124(4):917-924.
44. Sany J, Kaiser MJ, Jorgensen C, Trape G. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. Ann Rheum Dis. 2005;64(11):1647-1649.
45. Jacobstein DA, Markowitz JE, Kirschner BS, et al. Premedication and infusion reactions with infliximab: results from a pediatric infl ammatory bowel disease consortium. Inflamm Bowel Dis. 2005;11(5):442-446.
46. Saraceno R, Chimenti S. How to manage infections in the era of biologics? Dermatol Ther. 2008;21(3):180-186.
47. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000; 49(RR-6):1-51.
48. Raychaudhuri S, Shmerling R, Ermann J, Helfgott S. Development of active tuberculosis following initiation of infliximab despite appropriate prophylaxis. Rheumatology (Oxford). 2007;46(5):887-888.
49. Takahashi H, Shigehara K, Yamamoto M, et al. Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration. Rheumatol Int. 2007;27(12): 1143-1148.
50. Cohen RD, Bowie WR, Enns R, Flint J, Fitzgerald JM. Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease. Thorax. 2007;62(11):1013-1014.
51. Kesteman T, Yombi JC, Gigi J, Durez P. Listeria infections associated with infliximab: case reports. Clin Rheumatol. 2007;26(12):2173-2175.
52. Geraghty EM, Ristow B, Gordon SM, Aronowitz P. Overwhelming parasitemia with Plasmodium falciparum infection in a patient receiving infliximab therapy for rheumatoid arthritis. Clin Infect Dis. 2007;44(10): e82-e84.
53. Tektonidou MG, Skopouli FN. Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection? Clin Rheumatol. 2008;27(4):541-542.
54. Muñoz P, Giannella M, Valerio M, et al. Cryptococcal meningitis in a patient treated with infliximab. Diagn Microbiol Infect Dis. 2007;57(4):443-446.
55. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46(10): 2565-2570.
56. Rapp SR, Feldman SR. The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life? Dermatol Ther. 2004;17:376-382.
57. Fortune DG, Main CJ, O'Sullivan TM, Griffi ths CE. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specifi c stress. Br J Dermatol. 1997;137:755-760.
58. Feldman SR, Gottlieb AB, Bala M, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008;159:704-710.
59. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383-392.
60. Rigopoulos D, Gregoriou S, Stratigos A, et al. Evaluation of the efficacy and safety of Infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol. 2008;159(2):453-456.
61. De Jong EM, Seegers BA, Gulinck MK, Boezeman JB, van de Kerkhof PC. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology. 1996;193(4):300-303.
62. Cohen MR, Reda DJ, Clegg DO. Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol. 1999;26(8):1752-1756.
63. Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol. 1994;33(9):834-839.
64. Baker H, Golding DN, Thompson. The nails in psoriatic arthritis. Br J Dermatol. 1964;76:549-654.
65. Wright V, Roberts MC, Hill AG. Dermatological manifestations in psoriatic arthritis: a follow-up study. Acta Derm Venereol. 1979;59(3):235-240.
66. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA) - an analysis of 220 patients. Q J Med. 1987;62(238):127-141.
67. Tan AL, Benjamin M, Toumi H, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis - a high-resolution MRI and histological study. Rheumatology (Oxford). 2007;46(2):253-256.
68. Kane D, Stafford L, Bresnihan B, FitzGerald O. A classifi cation study of clinical subsets in an inception cohort of early psoriatic peripheral arthritis - 'DIP or not DIP revisited'. Rheumatology (Oxford). 2003;42(12):1469-1476.
69. Williamson L, Dalbeth N, Dockerty JL, Gee BC, Weatherall R, Wordsworth BP. Extended report: nail disease in psoriatic arthritis - clinically important, potentially treatable and often over-looked. Rheumatology (Oxford). 2004;43(6):790-794.
70. Scarpa R, Manguso F, Oriente A, Peluso R, Atteno M, Oriente P. Is the involvement of the distal interphalangeal joint in psoriatic patients related to nail psoriasis? Clin Rheumatol. 2004;23(1):27-30.
71. Serarslan G, Güler H, Karazincir S. The relationship between nail- and distal phalangeal bone involvement severity in patients with psoriasis. Clin Rheumatol. 2007;26(8):1245-1247.
72. Bianchi L, Bergamin A, de Felice C, Capriotti E, Chimenti S. Remission and time of resolution of nail psoriasis during Infliximab therapy. J Am Acad Dermatol. 2005;52(4):736-737.
73. Lawry M. Biological therapy and nail psoriasis. Dermatol Ther. 2007;20(1):60-67.
74. Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. A systematic review. J Rheumatol. 2006;33(7):1452-1456.
75. Taylor WJ. Epidemiology of psoriatic arthritis. Curr Opin Rheumatol. 2002;14(2):98-103.
76. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology. 2003;42(6):778-783.
77. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary defi nition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727-735.
78. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefi ts of Infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52(4): 1227-1236.
79. Antoni C, Krueger GG, de Vlam K, et al. IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis.2005;64(8):1150-1157.
80. Kavanaugh A, Antoni CE, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65(8): 1038-1043.
81. Reich K, Griffi ths C, Barker J, et al. Recommendations for the longterm treatment of psoriasis with Infliximab: a dermatology expert group consensus. Dermatology. 2008;217(3):268-275.